CytRx (CYTR) Surges as Aldoxorubicin Effective in Brain Cancer Animal Studies
Tweet
Share
E-mailGet Alerts CYTR Hot Sheet
Join SI Premium – FREE
CytRx Corporation (NASDAQ: CYTR) is ramping 35% early Tuesday after the company announced that aldoxorubicin, its more potent version of the widely used chemotherapeutic agent doxorubicin, demonstrated statistically significant efficacy (p<.0001) in the treatment of rapidly growing human brain (glioblastoma) cancer in the brains of animals.
Complete results from this favorable confirmatory trial, which was conducted in collaboration with Louisiana State University (LSU) School of Medicine, will be presented at the European Society for Medical Oncology being held September 29-October 1 2013 in Amsterdam.
Complete results from this favorable confirmatory trial, which was conducted in collaboration with Louisiana State University (LSU) School of Medicine, will be presented at the European Society for Medical Oncology being held September 29-October 1 2013 in Amsterdam.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Super Micro Computer (SMCI) Falls 6%
- DoorDash (DASH) Appoints Jeffrey Blackburn to its Board
- Asbury Automotive Group (ABG) Announces Retirement of Chief Legal Officer
Create E-mail Alert Related Categories
Corporate News, FDA, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
